Drugs / HS-IT201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06613152 | Oct 2024 → Oct 2026 expected | neoplasm | Qingdao Sino-Cell Biomedicine Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-IT201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06613152 ↗ |
| Modality | Cell therapy | “adoptive cell transfer therapy” NCT06613152 ↗ |
| Route | Intravenous | “Adoptive transfer of 5x10\^9-4x10\^10 autologous TIL to patients i.v. in 30-60 minutes.” NCT06613152 ↗ |